Stocklytics Platform
Asset logo for symbol KALA
Kala Pharmaceuticals
KALA50
$5.76arrow_drop_down2.53%-$0.15
Asset logo for symbol KALA
KALA50

$5.76

arrow_drop_down2.53%
Key Stats
Open$5.93
Prev. Close$5.91
EPS-13.52
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$32.39M
PE Ratio-
LOWHIGH
Day Range5.76
6.09
52 Week Range4.21
11.21
Ratios
Revenue-
EBITDA Margin %-
EPS-13.52
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.90%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

KALA-
US Healthcare Sector-
US Market-
warning

KALA / Market

KALA lose to the US Market which returned 0.79% over the last twenty four hours.
warning

KALA / Healthcare Sector

KALA lose to the US Healthcare sector which returned 0.44% over the last twenty four hours.

Kala Pharmaceuticals (KALA) Statistics

Kala Pharmaceuticals Inc. (KALA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. The company's lead product candidate is EYSUVIS™ (loteprednol etabonate ophthalmic suspension), a corticosteroid designed for the treatment of inflammation and pain following ocular surgery. KALA utilizes its proprietary Mucus Penetrating Particle (MPP) technology to enhance drug penetration and prolong drug release in the eye, which may improve therapeutic outcomes and patient compliance. The company is also exploring the potential of its MPP technology in other ocular and non-ocular indications.
When it comes to valuation metrics, KALA Pharmaceuticals Inc. is currently trading at a price-to-sales ratio of 24.81, indicating that the company is relatively overvalued compared to its industry peers. The company's price-to-earnings ratio (P/E ratio) stands at -6.23, suggesting that KALA Pharmaceuticals Inc. is currently not profitable. In terms of fundamentals, the company has a negative net income margin of -518.46%, indicating that it is not generating a profit. Additionally, KALA Pharmaceuticals Inc. has a total debt of $70.62 million, which could potentially affect its financial stability. However, it is important to note that these metrics can vary over time and should be interpreted in the context of industry trends and the company's specific circumstances.
add Kala Pharmaceuticals  to watchlist

Keep an eye on Kala Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Kala Pharmaceuticals (KALA) stock's performance compared to its sector and the market over the past year?

Over the past year, Kala Pharmaceuticals (KALA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.31%, Kala Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 63.77%, it has fallen short of the market average. This comparison highlights Kala Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Kala Pharmaceuticals (KALA) stock?

The PE ratio for Kala Pharmaceuticals (KALA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Kala Pharmaceuticals (KALA) stock?

The Earnings Per Share (EPS) for Kala Pharmaceuticals (KALA), calculated on a diluted basis, is -$13.52. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Kala Pharmaceuticals (KALA) stock?

The operating margin for Kala Pharmaceuticals (KALA) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Kala Pharmaceuticals (KALA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Kala Pharmaceuticals (KALA) is -$40.98M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Kala Pharmaceuticals (KALA) have?

Kala Pharmaceuticals (KALA) has a total debt of $36.8M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$17.4M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media